中国医院用药评价与分析2025，Vol.25Issue(5)：598-603,6.DOI:10.14009/j.issn.1672-2124.2025.05.018
依达拉奉右莰醇治疗急性缺血性脑卒中的快速卫生技术评估
Rapid Health Technology Assessment on Edaravone Dexborneol in the Treatment of Acute Ischemic Stroke
摘要
Abstract
OBJECTIVE:Based on rapid health technology,to conduct a comprehensive evaluation on efficacy,safety and economical efficiency of edaravone dexborneol in the clinical treatment of patients with acute ischemic stroke,so as to provide evidence-based and pharmacoeconomics evidence for clinical drug selection.METHODS:Systematic review/Meta-analysis,pharmacoeconomics studies and health technology assessment reports related to edaravone dexborneol in the treatment of acute ischemic stroke were collected by systematically searching Chinese and English databases including PubMed,the Cochrane Library,Embase,Web of Science,CNKI,SinoMed,VIP,Wanfang Data and websites of health technology assessment,the retrieval time was from database establishment to Jul.2024.Quality assessment on enrolled studies was conducted,qualitative description and analysis were performed after summarizing the research results.RESULTS:A total of 10 studies were enrolled,including 5 systematic reviews/Meta-analyses and 5 pharmacoeconomics studies,and no health technology assessment report was retrieved.Analysis results indicated that edaravone dexborneol had significant effects in improving patients'neurological functional prognosis and self-care ability of daily living,with remarkable clinical efficacy.In terms of safety,there was no statistically significant difference in the comparison of incidence of adverse drug reactions between edaravone dexborneol and other drugs(P>0.05),with higher safety.In terms of economical efficiency,edaravone dexborneol had economic advantages priority to edaravone,butyphthalide and Yureklin in patients with acute ischemic stroke in China.CONCLUSIONS:Edaravone dexborneol has demonstrated good efficacy,safety and cost-effectiveness in the treatment of acute ischemic stroke.While the efficacy and safety still need to be verified by high-quality randomized controlled trials,and its economical efficiency needs to be further evaluated based on the data from head-to-head clinical studies.关键词
依达拉奉右莰醇/急性缺血性脑卒中/有效性/安全性/经济性/快速卫生技术评估Key words
Edaravone dexborneol/Acute ischemic stroke/Efficacy/Safety/Economical efficiency/Rapid health technology assessment分类
医药卫生引用本文复制引用
刘成裕,刘代华,覃方,韩晓龙,韦玥吟,覃兰,刘至玲,谭畅..依达拉奉右莰醇治疗急性缺血性脑卒中的快速卫生技术评估[J].中国医院用药评价与分析,2025,25(5):598-603,6.基金项目
2022-2023年度广西壮族自治区卫生健康委药品临床综合评价课题(No.YPPJ010) （No.YPPJ010）
